الفهرس Only 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
SUMMARY & CONCLUSION
P
rimary hyperhidrosis is a common disorder that can cause serious social, psychological, and occupational problems. It is estimated to affect 0.6-1.0% of the population. Primary hyperhidrosis may be defined as excessive, uncontrollable sweating in the absence of a discernible cause, and it is most commonly limited to the axillae, palms, or soles. While secondary hyperhidrosis occurs as a disorder resulting from certain diseases like diabetes mellitus or as a side effect of some drugs like fluoxetine and ibuprofen. br>Recently, botulinum toxins are used in the field of treatment of primary hyperhidrosis. Botulinum toxins are a family of neurotoxins produced by the anaerobic bacteria Clostridium botulinum. The most used type among them is botulinum toxin-A which has been used in clinical medicine for several applications. Botulinum toxin-A acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Its therapeutic effect was used initially to block the neuromuscular junction in order to relieve increased muscle tone. In the last few years, the blocking action of BTX-A on cholinergically innervated sweat glands has been used to treat patients with focal hyperhidrosis of the axillae and palms. BTX-A is commercially available in two forms; Botox® and Dysport®.
In this thesis, we used Botox vial in the treatment of palmar and axillary hyperhidrosis. Four patients (2 palmar & 2 axillary) participated in this study, they were injected with Botox intradermally in an approximate total dose of 60U-70U per palm and 30U-40U per axilla.
The results were evaluated after one week of injection, then monthly for a year. The patients’ assessment was positive, and the improvement of hyperhidrosis was clinically proven by Minor’s starch-iodine test. Assessment of both extent and duration of action was done in the follow up visits; relapse occurred after 7-11 months in palm and 6-7 months in axilla.
In conclusion, it was found that intradermal injection of botulinum toxin-A is a safe, effective, relatively long acting, and well accepted approach to cope with primary hyperhidrosis.
SUMMARY & CONCLUSION
P
rimary hyperhidrosis is a common disorder that can cause serious social, psychological, and occupational problems. It is estimated to affect 0.6-1.0% of the population. Primary hyperhidrosis may be defined as excessive, uncontrollable sweating in the absence of a discernible cause, and it is most commonly limited to the axillae, palms, or soles. While secondary hyperhidrosis occurs as a disorder resulting from certain diseases like diabetes mellitus or as a side effect of some drugs like fluoxetine and ibuprofen.
Recently, botulinum toxins are used in the field of treatment of primary hyperhidrosis. Botulinum toxins are a family of neurotoxins produced by the anaerobic bacteria Clostridium botulinum. The most used type among them is botulinum toxin-A which has been used in clinical medicine for several applications. Botulinum toxin-A acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Its therapeutic effect was used initially to block the neuromuscular junction in order to relieve increased muscle tone. In the last few years, the blocking action of BTX-A on cholinergically innervated sweat glands has been used to treat patients with focal hyperhidrosis of the axillae and palms. BTX-A is commercially available in two forms; Botox® and Dysport®.
In this thesis, we used Botox vial in the treatment of palmar and axillary hyperhidrosis. Four patients (2 palmar & 2 axillary) participated in this study, they were injected with Botox intradermally in an approximate total dose of 60U-70U per palm and 30U-40U per axilla.
The results were evaluated after one week of injection, then monthly for a year. The patients’ assessment was positive, and the improvement of hyperhidrosis was clinically proven by Minor’s starch-iodine test. Assessment of both extent and duration of action was done in the follow up visits; relapse occurred after 7-11 months in palm and 6-7 months in axilla.
In conclusion, it was found that intradermal injection of botulinum toxin-A is a safe, effective, relatively long acting, and well accepted approach to cope with primary hyperhidrosis.
SUMMARY & CONCLUSION
P
rimary hyperhidrosis is a common disorder that can cause serious social, psychological, and occupational problems. It is estimated to affect 0.6-1.0% of the population. Primary hyperhidrosis may be defined as excessive, uncontrollable sweating in the absence of a discernible cause, and it is most commonly limited to the axillae, palms, or soles. While secondary hyperhidrosis occurs as a disorder resulting from certain diseases like diabetes mellitus or as a side effect of some drugs like fluoxetine and ibuprofen.
Recently, botulinum toxins are used in the field of treatment of primary hyperhidrosis. Botulinum toxins are a family of neurotoxins produced by the anaerobic bacteria Clostridium botulinum. The most used type among them is botulinum toxin-A which has been used in clinical medicine for several applications. Botulinum toxin-A acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Its therapeutic effect was used initially to block the neuromuscular junction in order to relieve increased muscle tone. In the last few years, the blocking action of BTX-A on cholinergically innervated sweat glands has been used to treat patients with focal hyperhidrosis of the axillae and palms. BTX-A is commercially available in two forms; Botox® and Dysport®.
In this thesis, we used Botox vial in the treatment of palmar and axillary hyperhidrosis. Four patients (2 palmar & 2 axillary) participated in this study, they were injected with Botox intradermally in an approximate total dose of 60U-70U per palm and 30U-40U per axilla.
The results were evaluated after one week of injection, then monthly for a year. The patients’ assessment was positive, and the improvement of hyperhidrosis was clinically proven by Minor’s starch-iodine test. Assessment of both extent and duration of action was done in the follow up visits; relapse occurred after 7-11 months in palm and 6-7 months in axilla.
In conclusion, it was found that intradermal injection of botulinum toxin-A is a safe, effective, relatively long acting, and well accepted approach to cope with primary hyperhidrosis.
SUMMARY & CONCLUSION
P
rimary hyperhidrosis is a common disorder that can cause serious social, psychological, and occupational problems. It is estimated to affect 0.6-1.0% of the population. Primary hyperhidrosis may be defined as excessive, uncontrollable sweating in the absence of a discernible cause, and it is most commonly limited to the axillae, palms, or soles. While secondary hyperhidrosis occurs as a disorder resulting from certain diseases like diabetes mellitus or as a side effect of some drugs like fluoxetine and ibuprofen.
Recently, botulinum toxins are used in the field of treatment of primary hyperhidrosis. Botulinum toxins are a family of neurotoxins produced by the anaerobic bacteria Clostridium botulinum. The most used type among them is botulinum toxin-A which has been used in clinical medicine for several applications. Botulinum toxin-A acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Its therapeutic effect was used initially to block the neuromuscular junction in order to relieve increased muscle tone. In the last few years, the blocking action of BTX-A on cholinergically innervated sweat glands has been used to treat patients with focal hyperhidrosis of the axillae and palms. BTX-A is commercially available in two forms; Botox® and Dysport®.
In this thesis, we used Botox vial in the treatment of palmar and axillary hyperhidrosis. Four patients (2 palmar & 2 axillary) participated in this study, they were injected with Botox intradermally in an approximate total dose of 60U-70U per palm and 30U-40U per axilla.
The results were evaluated after one week of injection, then monthly for a year. The patients’ assessment was positive, and the improvement of hyperhidrosis was clinically proven by Minor’s starch-iodine test. Assessment of both extent and duration of action was done in the follow up visits; relapse occurred after 7-11 months in palm and 6-7 months in axilla.
In conclusion, it was found that intradermal injection of botulinum toxin-A is a safe, effective, relatively long acting, and well accepted approach to cope with primary hyperhidrosis.
SUMMARY & CONCLUSION
P
rimary hyperhidrosis is a common disorder that can cause serious social, psychological, and occupational problems. It is estimated to affect 0.6-1.0% of the population. Primary hyperhidrosis may be defined as excessive, uncontrollable sweating in the absence of a discernible cause, and it is most commonly limited to the axillae, palms, or soles. While secondary hyperhidrosis occurs as a disorder resulting from certain diseases like diabetes mellitus or as a side effect of some drugs like fluoxetine and ibuprofen.
Recently, botulinum toxins are used in the field of treatment of primary hyperhidrosis. Botulinum toxins are a family of neurotoxins produced by the anaerobic bacteria Clostridium botulinum. The most used type among them is botulinum toxin-A which has been used in clinical medicine for several applications. Botulinum toxin-A acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Its therapeutic effect was used initially to block the neuromuscular junction in order to relieve increased muscle tone. In the last few years, the blocking action of BTX-A on cholinergically innervated sweat glands has been used to treat patients with focal hyperhidrosis of the axillae and palms. BTX-A is commercially available in two forms; Botox® and Dysport®.
In this thesis, we used Botox vial in the treatment of palmar and axillary hyperhidrosis. Four patients (2 palmar & 2 axillary) participated in this study, they were injected with Botox intradermally in an approximate total dose of 60U-70U per palm and 30U-40U per axilla.
The results were evaluated after one week of injection, then monthly for a year. The patients’ assessment was positive, and the improvement of hyperhidrosis was clinically proven by Minor’s starch-iodine test. Assessment of both extent and duration of action was done in the follow up visits; relapse occurred after 7-11 months in palm and 6-7 months in axilla.